Post-transplant lymphoproliferative disorder: the significance of central nervous system disease.
Carlos E
CE
Araya
D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000175:diagnosis* / Q000209:etiology*; D002648:Child; D016503:Drug Delivery Systems; D020031:Epstein-Barr Virus Infections / Q000209:etiology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D057967:Infusions, Intraventricular; D008223:Lymphoma / Q000628:therapy; D008232:Lymphoproliferative Disorders / Q000175:diagnosis* / Q000209:etiology*; D008970:Molecular Weight; D010372:Pediatrics / Q000379:methods; D011183:Postoperative Complications; D000069283:Rituximab; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D007166:Immunosuppressive Agents; D000069283:Rituximab